Shilpa Medicare Announces Positive Phase 3 Results for OERIS A Novel Once‐Weekly Ondansetron Extended‐Release Injection for Chemotherapy‐Induced Nausea and Vomiting (CINV)
SHILPAMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Shilpa Medicare has announced successful Phase 3 clinical trial results for OERIS, a novel once-weekly extended-release injectable formulation of Ondansetron aimed at preventing chemotherapy-induced nausea and vomiting (CINV). The product offers a more convenient dosing schedule compared to conventional multiple-dose regimens used in cancer care. Positive Phase 3 outcomes are a critical late-stage milestone that clears the path for the company to seek marketing approval from regulators such as the US FDA and Indian drug authorities. OERIS targets the well-established CINV market, where improved dosing convenience could support differentiation and adoption. Management has not yet disclosed expected filing timelines or potential commercialization paths, which will be key for investors to track.
The news is positive for shareholders as it removes the largest clinical risk hurdle and strengthens the company's specialty injectables pipeline. Near-term stock reaction may be favorable, but sustained gains will depend on regulatory filing progress, eventual approval, and any licensing or commercialisation partnerships.